{"id":"https://genegraph.clinicalgenome.org/r/65c128de-2e37-4596-8687-4c783a2f34bbv1.0","type":"EvidenceStrengthAssertion","dc:description":"DNASE1L3 is encoded on chromosome 3. It is one of several human homologs of DNase I. The family of enzymes includes DNASE1, DNASE1L1, DNASE1L2 and DNASE1L3. These function as endonucleases capable of cleaving DNA. DNASE1L3, predominantly expressed in macrophages and dendritic cells (unlike the other DNase homologs, which are expressed at much lower levels in hematopoietic cells), is secreted into the circulation and is thought to have a role in the fragmentation of free plasma DNA, clearing it from circulation and reducing risk of cell-free DNA antigenicity. \n\nDNASE1L3 was first reported in relation to autosomal recessive monogenic Systemic Lupus Erythematosus (SLE) in 2011 (PMID: 22019780). At least 5 loss-of-function genetic variants (missense, nonsense, frameshift, large deletion) have been reported in humans, commonly in children from consanguineous marriages. Evidence supporting this gene-disease relationship includes multiple reports of case-level data. The initial 2011 report (PMID: 22019780) described a homozygous 1-bp deletion (c.289_290 del) in DNASE1L3 in six individuals diagnosed with childhood-onset SLE, based on clinical and serological criteria. Additional cases of childhood-onset SLE with the same base-pair deletions were reported in 2017 (PMID: 27821515), 2018 (PMID: 30008451) and 2020 (PMID: 34161863). Additional variants in the DNASE1L3 gene with manifestations of SLE and/or lupus nephritis were reported in a case series in 2021 (PMID: 35670985). \n\nThis gene-disease relationship is supported by expression studies showing that the c.289_290 deletion mutation is associated with decreased expression of *DNASE1L3* RNA levels (PMID: 23666765). A SNP in *DNASE1L3* that is associated with increased SLE risk was also shown to be associated with decreased protein secretion of DNASE1L3 (PMID: 33455918). Decreased serum levels of DNASE1L3 are observed in the general SLE (and inflammatory myositis) population as compared to healthy controls; in SLE, lower DNASE1L3 levels are associated with higher clinical disease scores (PMID: 28039554). Animal models show that mice with DNASE1L3 deletion develop anti-DNA autoantibodies and lupus nephritis (PMID: 28039554). Deletion of *DNASE1L3* resulted in aberrations in the fragmentation of plasma DNA (PMID: 30593563); these aberrant DNA fragments were also present in the circulation of patients with the *DNASE1L3* disease-associated variants, but not in healthy controls (PMID: 33022220). In mice with the *DNASE1L3* deletion, the phenotype of aberrant DNA fragments in the peripheral circulation could be rescued by restoring DNASE1L3 production using viral vectors (PMID: 33022220).\n\nMore evidence is available in the literature, but the maximum score for genetic and experimental evidence (18 pts.) has been reached. The mechanism for disease is homozygous loss of function.\n  \nIn summary, there is definitive evidence to support the relationship between *DNASE1L3* and autosomal recessive monogenic Systemic Lupus Erythematosus. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time.\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/65c128de-2e37-4596-8687-4c783a2f34bb","GCISnapshot":"https://genegraph.clinicalgenome.org/r/77450e46-30fa-4be0-aa0e-4e31f04a117e","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/77450e46-30fa-4be0-aa0e-4e31f04a117e_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10123","date":"2024-06-14T17:02:13.944Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/77450e46-30fa-4be0-aa0e-4e31f04a117e_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10123","date":"2024-05-08T19:00:00.000Z","role":"Approver"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/77450e46-30fa-4be0-aa0e-4e31f04a117e_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c0a8c912-3c1e-401d-9643-db6265d1af74_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0e5ff618-0bc7-41c0-81cf-aa862d03eb92","type":"EvidenceLine","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0e5ff618-0bc7-41c0-81cf-aa862d03eb92_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Using a minigene assay, this variant was shown to lead to exon 4 skipping, shifting the reading frame and terminating at position Ter19.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/0e5ff618-0bc7-41c0-81cf-aa862d03eb92_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35670985","allele":{"id":"https://genegraph.clinicalgenome.org/r/880d234c-d641-40b8-97f6-b7cbc04a3488","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004944.4(DNASE1L3):c.433G>A (p.Ala145Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2470017"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/c0a8c912-3c1e-401d-9643-db6265d1af74","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35670985","rdfs:label":"Tusseau Pt2","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":11,"allele":{"id":"https://genegraph.clinicalgenome.org/r/880d234c-d641-40b8-97f6-b7cbc04a3488"},"detectionMethod":"Coding regions of the DNASE1L3 gene were directly sequenced by Sanger sequencing.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"The patient is a young girl from Arab descent. The disease started at 11 years with bilateral arthralgia associated with a chronic atypical urticaria. After few months of evolution, she presented a lupus like glomerulonephritis with increases in serum creatinine (88 Âµmol/L) and moderate proteinuria (1.28 g/L, 145 mg/mmol) and hematuria. A renal biopsy confirmed an immune complex glomerulonephritis. The titer of ANA was positive (1:320), as well as ANCA with anti-MPO specificity (5 IA). Both C3 and C4 levels were reduced (565mg/L and 117 mg/L respectively). CRP was normal but ESR was elevated (107).","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/0e5ff618-0bc7-41c0-81cf-aa862d03eb92_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/06401e09-613e-40ad-b018-dc311698b40c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b3e0eee7-14a9-4b8b-8d24-92b64b3a7ae5","type":"EvidenceLine","dc:description":"No diagnostics criteria or other information were given for this subject.","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b3e0eee7-14a9-4b8b-8d24-92b64b3a7ae5_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Reported by Ueki et al. (PMID 19559017), this variant protein showed no DNase activity as assayed by single radial enzyme diffusion (SRED) method with crude cell lysates. A later report by Coke et al. (PMID 33455918) showed that the DNASE1L3 p.Arg206Cys variant dramatically reduces its secretion, although the protein retains DNase activity.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/b3e0eee7-14a9-4b8b-8d24-92b64b3a7ae5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22019780","allele":{"id":"https://genegraph.clinicalgenome.org/r/6e981505-6d67-4931-8448-f51614aea07c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004944.4(DNASE1L3):c.616C>T (p.Arg206Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2469909"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/06401e09-613e-40ad-b018-dc311698b40c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22019780","rdfs:label":"Al-Mayouf sporadic SLE subject 1","allele":{"id":"https://genegraph.clinicalgenome.org/r/6e981505-6d67-4931-8448-f51614aea07c"},"detectionMethod":"In a set of 85 subjects with sporadic SLE, the investigators searched for runs of homozygosity overlapping with the DNASE1L3 locus. 8 subjects showed overlap, and of those subjects, one showed a homozygous variant leading to the R206C substitution reported here.","firstTestingMethod":"Homozygosity mapping","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/b3e0eee7-14a9-4b8b-8d24-92b64b3a7ae5_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/7a128c13-a8ef-4591-aa1e-a3803f06fab8_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4189583e-13c8-4805-a4ea-01226e1d3ac6","type":"EvidenceLine","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4189583e-13c8-4805-a4ea-01226e1d3ac6_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"qPCR in a homozygous carrier showed significantly reduced expression; PMID 23666765","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/4189583e-13c8-4805-a4ea-01226e1d3ac6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34161863","allele":{"id":"https://genegraph.clinicalgenome.org/r/8ca27d60-178b-4f7e-be35-f09e85eb3164","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004944.4(DNASE1L3):c.290_291del (p.Thr97fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/1172533"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/7a128c13-a8ef-4591-aa1e-a3803f06fab8","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34161863","rdfs:label":"Ekinci_Proband 1","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":15,"allele":{"id":"https://genegraph.clinicalgenome.org/r/8ca27d60-178b-4f7e-be35-f09e85eb3164"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"recurrent urticarial rash and hemoptysis, precipitated by wheat and milk consumption; elevated milk-specific IgE, microscopic hematuria, mild proteinuria, decreased serum complement components C3 (62 mg/dl) and C4 (6.8 mg/dl), ANA positivity (1/100 titer), anti-dsDNA positivity (34.3 IU/ml), antineutrophil cytoplasmic antibodies (ANCA) positivity, negative celiac antibodies and antibodies to extractable nuclear antigens; immunocomplex glomerulonephritis with mesangial staining for C3, C4, IgG, and C1q","phenotypes":["obo:HP_0032230","obo:HP_0020151"],"previousTesting":false,"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/4189583e-13c8-4805-a4ea-01226e1d3ac6_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/4bf1b2cf-1e1b-4839-be5a-73307b8e78aa_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/433a5867-2846-4835-bf04-130a497fac0a","type":"EvidenceLine","dc:description":"Only one proband from the families in the Al Mayouf et al. paper will be scored; these families carry a single variant in DNASE1L3 that may be due to a founder mutation. The evidence would otherwise be overweighted.","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/433a5867-2846-4835-bf04-130a497fac0a_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"No DNASE1L3 transcript was detectable in two patient lymphoblast cell lines carrying the homozygous DNASE1L3 c.643del variant.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/433a5867-2846-4835-bf04-130a497fac0a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22019780","allele":{"id":"https://genegraph.clinicalgenome.org/r/f023dc4c-022d-4ebe-9f1b-f9a6cf2bf8ac","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004944.4(DNASE1L3):c.643del (p.Trp215GlyfsTer2)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA913187419"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/4bf1b2cf-1e1b-4839-be5a-73307b8e78aa","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22019780","rdfs:label":"Al-Mayouf F2-A","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":3,"allele":{"id":"https://genegraph.clinicalgenome.org/r/f023dc4c-022d-4ebe-9f1b-f9a6cf2bf8ac"},"detectionMethod":"Autozygome analysis identified overlapping autozygous intervals of varying lengths at 3p14.3 among six consanguineous families affected by SLE. Linkage analysis confirmed this to be a genuine linkage locus with LOD score 6.6. The minimal linkage interval contained 206 genes, including DNASE1L3. DNASE1L3 was identified as a top candidate gene and subsequently sequenced.","firstTestingMethod":"Linkage analysis","phenotypeFreeText":"anti-nuclear antibody, low c3 and c4, anti-cardiolipin; SLE activity index 11","phenotypes":["obo:HP_0033726","obo:HP_0032230","obo:HP_0020151"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/433a5867-2846-4835-bf04-130a497fac0a_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/85e3bd14-8a7d-43c1-a327-e2e085462aa5_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/205b3d24-3262-40ca-b0e3-5e061b147929","type":"EvidenceLine","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/205b3d24-3262-40ca-b0e3-5e061b147929_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"No DNASE1L3 transcript was detectable in two patient lymphoblast cell lines carrying the homozygous DNASE1L3 c.643del variant.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/205b3d24-3262-40ca-b0e3-5e061b147929_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22019780","allele":{"id":"https://genegraph.clinicalgenome.org/r/f023dc4c-022d-4ebe-9f1b-f9a6cf2bf8ac"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/85e3bd14-8a7d-43c1-a327-e2e085462aa5","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22019780","rdfs:label":"Al-Mayouf F1-A","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":2,"allele":{"id":"https://genegraph.clinicalgenome.org/r/f023dc4c-022d-4ebe-9f1b-f9a6cf2bf8ac"},"detectionMethod":"Autozygome analysis identified overlapping autozygous intervals of varying lengths at 3p14.3 among six consanguinenous families affected by SLE. Linkage analysis confirmed this to be a genuine linkage locus with LOD score 6.6. The minimal linkage interval contained 206 genes, including DNASE1L3. DNASE1L3 was identified as a top candidate gene and subsequently sequenced.","firstTestingMethod":"Linkage analysis","phenotypeFreeText":"anti-nuclear antibody, low c3 and c4; SLE activity index 13","phenotypes":["obo:HP_0032230","obo:HP_0020151"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/205b3d24-3262-40ca-b0e3-5e061b147929_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/0f132d68-2af9-4d94-a90e-f24d8920e2de_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5e7754a6-9d4d-4bcc-a03c-1181d8936dfe","type":"EvidenceLine","dc:description":"Only one proband from the families in the Al Mayouf et al. paper will be scored; these families carry a single variant in DNASE1L3 that may be due to a founder mutation. The evidence would otherwise be overweighted.","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5e7754a6-9d4d-4bcc-a03c-1181d8936dfe_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"No DNASE1L3 transcript was detectable in two patient lymphoblast cell lines carrying the homozygous DNASE1L3 c.643del variant.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/5e7754a6-9d4d-4bcc-a03c-1181d8936dfe_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22019780","allele":{"id":"https://genegraph.clinicalgenome.org/r/f023dc4c-022d-4ebe-9f1b-f9a6cf2bf8ac"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/0f132d68-2af9-4d94-a90e-f24d8920e2de","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22019780","rdfs:label":"Al-Mayouf F5-A","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":3,"allele":{"id":"https://genegraph.clinicalgenome.org/r/f023dc4c-022d-4ebe-9f1b-f9a6cf2bf8ac"},"detectionMethod":"Autozygome analysis identified overlapping autozygous intervals of varying lengths at 3p14.3 among six consanguinenous families affected by SLE. Linkage analysis confirmed this to be a genuine linkage locus with LOD score 6.6. The minimal linkage interval contained 206 genes, including DNASE1L3. DNASE1L3 was identified as a top candidate gene and subsequently sequenced.","firstTestingMethod":"Linkage analysis","phenotypeFreeText":"anti-nuclear antibody, low c3 and c4; SLE activity index 14","phenotypes":["obo:HP_0033726","obo:HP_0020151"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/5e7754a6-9d4d-4bcc-a03c-1181d8936dfe_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/99bcd25e-3b5e-486c-b0e5-ac14146d034a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cc3a6d65-2de0-4608-8ff8-889fd5c47021","type":"EvidenceLine","dc:description":"Only one proband from the families in the Al Mayouf et al. paper will be scored; these families carry a single variant in DNASE1L3 that may be due to a founder mutation. The evidence would otherwise be overweighted.","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cc3a6d65-2de0-4608-8ff8-889fd5c47021_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"No DNASE1L3 transcript was detectable in two patient lymphoblast cell lines carrying the homozygous DNASE1L3 c.643del variant.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/cc3a6d65-2de0-4608-8ff8-889fd5c47021_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22019780","allele":{"id":"https://genegraph.clinicalgenome.org/r/f023dc4c-022d-4ebe-9f1b-f9a6cf2bf8ac"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/99bcd25e-3b5e-486c-b0e5-ac14146d034a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22019780","rdfs:label":"Al-Mayouf F4-A","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":54,"allele":{"id":"https://genegraph.clinicalgenome.org/r/f023dc4c-022d-4ebe-9f1b-f9a6cf2bf8ac"},"detectionMethod":"Autozygome analysis identified overlapping autozygous intervals of varying lengths at 3p14.3 among six consanguinenous families affected by SLE. Linkage analysis confirmed this to be a genuine linkage locus with LOD score 6.6. The minimal linkage interval contained 206 genes, including DNASE1L3. DNASE1L3 was identified as a top candidate gene and subsequently sequenced.","firstTestingMethod":"Linkage analysis","phenotypeFreeText":"anti-nuclear antibody, low c3 and c4; SLE activity index 13","phenotypes":["obo:HP_0032230","obo:HP_0020151"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/cc3a6d65-2de0-4608-8ff8-889fd5c47021_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/7ff944d8-e6e2-49b6-9a6a-b4aab8c930b8_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4c1992fd-17d4-4b68-adb7-0b579a610dec","type":"EvidenceLine","dc:description":"Only one proband from the families in the Al Mayouf et al. paper will be scored; these families carry a single variant in DNASE1L3 that may be due to a founder mutation. The evidence would otherwise be overweighted.","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4c1992fd-17d4-4b68-adb7-0b579a610dec_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"No DNASE1L3 transcript was detectable in two patient lymphoblast cell lines carrying the homozygous DNASE1L3 c.643del variant.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/4c1992fd-17d4-4b68-adb7-0b579a610dec_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22019780","allele":{"id":"https://genegraph.clinicalgenome.org/r/f023dc4c-022d-4ebe-9f1b-f9a6cf2bf8ac"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/7ff944d8-e6e2-49b6-9a6a-b4aab8c930b8","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22019780","rdfs:label":"Al-Mayouf F6-A","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":6,"allele":{"id":"https://genegraph.clinicalgenome.org/r/f023dc4c-022d-4ebe-9f1b-f9a6cf2bf8ac"},"detectionMethod":"Autozygome analysis identified overlapping autozygous intervals of varying lengths at 3p14.3 among six consanguinenous families affected by SLE. Linkage analysis confirmed this to be a genuine linkage locus with LOD score 6.6. The minimal linkage interval contained 206 genes, including DNASE1L3. DNASE1L3 was identified as a top candidate gene and subsequently sequenced.","firstTestingMethod":"Linkage analysis","phenotypeFreeText":"anti-nuclear antibody, low c3 and c4; SLE activity index 10","phenotypes":"obo:HP_0020151","previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/4c1992fd-17d4-4b68-adb7-0b579a610dec_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/1e1a859d-d497-424e-b5c4-51bba450075b_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5d3d3d68-2518-4fdb-b89e-722dfc8bf6b3","type":"EvidenceLine","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5d3d3d68-2518-4fdb-b89e-722dfc8bf6b3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35670985","allele":{"id":"https://genegraph.clinicalgenome.org/r/f023dc4c-022d-4ebe-9f1b-f9a6cf2bf8ac"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/1e1a859d-d497-424e-b5c4-51bba450075b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35670985","rdfs:label":"Tusseau Pt4","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":18,"allele":{"id":"https://genegraph.clinicalgenome.org/r/f023dc4c-022d-4ebe-9f1b-f9a6cf2bf8ac"},"detectionMethod":"\"genetic analysis was carried out using the NGS TruSightOne Panel (Illumina) that target up to 6700 genes associated with human diseases\"","firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"Pt 4 is a boy whose symptoms started at the age of 18 months with stomachache, vomiting and diarrhea. He also presented urticaria repeating 7-15 days along with macular rash and arthritis. Biopsy of a skin showed leukocytoclastic vasculitis and endoscopy revealed lymphocytic and eosinophilic infiltration in the small intestine and colona bowel inflammation. Histopathology showed a chronic bowel inflammation with gut eosinophil infiltration. Then, from the age of 5-6 years old, he presented marked systemic inflammation with febrile episodes that were treated with steroids, antihistamine, antimalarials, immunosuppressive therapy and rituximab. The symptoms were improved by repeated courses of rituximab, but he did not achieve sustained disease remission. At age of 10.5 years, he developed new type of skin involvement with bullous and hemorrhagic vasculitis, and serological signs of SLE with positive ANA, anti-dsDNA, anticardiolipin antibodies and lupus anticoagulants. Gastrointestinal symptoms and skin rash were still occurring at the age of 10, and ANA were positive associated with high TNF-alpha and IL-6 and low levels of C3.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/5d3d3d68-2518-4fdb-b89e-722dfc8bf6b3_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/64c0b894-d8df-4609-9d7d-f0e877c25187_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/065e8089-8dd9-439d-a608-8ab4efd675ce","type":"EvidenceLine","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/065e8089-8dd9-439d-a608-8ab4efd675ce_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35670985","allele":{"id":"https://genegraph.clinicalgenome.org/r/80ae24e4-220b-4479-bb6d-76f6409980fc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004944.4(DNASE1L3):c.581G>A (p.Cys194Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA353338698"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/64c0b894-d8df-4609-9d7d-f0e877c25187","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35670985","rdfs:label":"Tusseau Pt5","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":4,"allele":{"id":"https://genegraph.clinicalgenome.org/r/80ae24e4-220b-4479-bb6d-76f6409980fc"},"firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"A previously healthy girl presented at the age of four with pain in her lower extremities, severe anemia, proteinuria, hematuria, hypertension, and acute kidney injury. Before admission, she had two episodes of unexplained urticaria. Initial laboratory testing revealed hypocomplementemia, highly positive anti-C1q antibodies, and positive anti-neutrophil cytoplasmic antibodies (ANCA). Serological markers of SLE were negative, except for anticardiolipin antibodies. Her clinical condition deteriorated rapidly. A kidney biopsy performed four days after admission demonstrated a severe, unusual form of immune complex-mediated glomerulonephritis, including glomerular, tubulointerstitial, and vascular lesions. Notably, advanced chronic sclerosing lesions were already present. The histopathology was found to be consistent with small vessel vasculitis. Atypical systemic lupus erythematosus (SLE) and hypocomplementemic urticarial vasculitis syndrome were considered.\nDespite aggressive treatment with methylprednisolone, cyclophosphamide, rituximab, plasmapheresis and hemodialysis, her kidney function never recovered. She is currently undergoing maintenance hemodialysis. All immunosuppressive drugs were gradually weaned off. Subsequently, subtle cutaneous vasculitis manifestations involving her palms and soles were noticed, and mycophenolate mofetil and hydroxychloroquine were introduced.\nThe work-up for kidney transplantation prompted a reevaluation of her histopathology. A more accurate diagnosis was required to predict future management and graft outcomes.\n","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/065e8089-8dd9-439d-a608-8ab4efd675ce_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/77450e46-30fa-4be0-aa0e-4e31f04a117e_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d925be50-28c1-4923-a8d5-0188beb8574f_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34161863","rdfs:label":"Ekinci_Family 1","estimatedLodScore":0.25,"family":{"id":"https://genegraph.clinicalgenome.org/r/d925be50-28c1-4923-a8d5-0188beb8574f","type":"Family","rdfs:label":"Ekinci_Family 1","member":{"id":"https://genegraph.clinicalgenome.org/r/7a128c13-a8ef-4591-aa1e-a3803f06fab8"}},"meetsInclusionCriteria":false,"phenotypeFreeText":"ANA positive, dsDNA positive, low complements, lupus nephritis biopsy confirmed, recurrent urticarial rash","phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":1,"proband":{"id":"https://genegraph.clinicalgenome.org/r/7a128c13-a8ef-4591-aa1e-a3803f06fab8"}},{"id":"https://genegraph.clinicalgenome.org/r/fca3eab2-13d1-46c2-b7eb-103533af0bd0_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22019780","rdfs:label":"Al-Mayouf F4","estimatedLodScore":0.73,"family":{"id":"https://genegraph.clinicalgenome.org/r/fca3eab2-13d1-46c2-b7eb-103533af0bd0","type":"Family","rdfs:label":"Al-Mayouf F4","member":{"id":"https://genegraph.clinicalgenome.org/r/99bcd25e-3b5e-486c-b0e5-ac14146d034a"}},"meetsInclusionCriteria":false,"phenotypeFreeText":"anti-nuclear antibody, low c3 and c4","phenotypeNegativeAlleleNegative":1,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0020151","obo:HP_0032230"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/99bcd25e-3b5e-486c-b0e5-ac14146d034a"}},{"id":"https://genegraph.clinicalgenome.org/r/dd9ada81-1a85-4cab-a59e-c80a1560a587_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22019780","rdfs:label":"Al-Mayouf F2","estimatedLodScore":1.83,"family":{"id":"https://genegraph.clinicalgenome.org/r/dd9ada81-1a85-4cab-a59e-c80a1560a587","type":"Family","rdfs:label":"Al-Mayouf F2","member":{"id":"https://genegraph.clinicalgenome.org/r/4bf1b2cf-1e1b-4839-be5a-73307b8e78aa"}},"meetsInclusionCriteria":false,"phenotypeFreeText":"anti-nuclear antibody, low c3 and c4, anti-cardiolipin","phenotypeNegativeAlleleNegative":5,"phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0020151","obo:HP_0032230","obo:HP_0033726"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/4bf1b2cf-1e1b-4839-be5a-73307b8e78aa"}},{"id":"https://genegraph.clinicalgenome.org/r/f2d62a87-2f3a-440e-9d13-4fdfa92ec2b1_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35670985","rdfs:label":"Tusseau Family D","family":{"id":"https://genegraph.clinicalgenome.org/r/f2d62a87-2f3a-440e-9d13-4fdfa92ec2b1","type":"Family","rdfs:label":"Tusseau Family D","member":{"id":"https://genegraph.clinicalgenome.org/r/1e1a859d-d497-424e-b5c4-51bba450075b"}},"phenotypePositiveAllelePositive":1,"proband":{"id":"https://genegraph.clinicalgenome.org/r/1e1a859d-d497-424e-b5c4-51bba450075b"}},{"id":"https://genegraph.clinicalgenome.org/r/3decd59e-b044-4f83-8237-67c4d64fbb63_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35670985","rdfs:label":"Tusseau Family B","estimatedLodScore":0.25,"family":{"id":"https://genegraph.clinicalgenome.org/r/3decd59e-b044-4f83-8237-67c4d64fbb63","type":"Family","rdfs:label":"Tusseau Family B","member":{"id":"https://genegraph.clinicalgenome.org/r/c0a8c912-3c1e-401d-9643-db6265d1af74"}},"phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":1,"proband":{"id":"https://genegraph.clinicalgenome.org/r/c0a8c912-3c1e-401d-9643-db6265d1af74"}},{"id":"https://genegraph.clinicalgenome.org/r/3e21801a-d620-4696-be21-bdc42fb1e119_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27821515","rdfs:label":"Carbonella_Family1","estimatedLodScore":1.93,"family":{"id":"https://genegraph.clinicalgenome.org/r/3e21801a-d620-4696-be21-bdc42fb1e119","type":"Family","rdfs:label":"Carbonella_Family1","member":{"id":"https://genegraph.clinicalgenome.org/r/3b1972e8-b2cb-476a-98ce-be8ce1609b0c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27821515","rdfs:label":"Carbonella et al. IV-3","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":17,"allele":{"id":"https://genegraph.clinicalgenome.org/r/8ca27d60-178b-4f7e-be35-f09e85eb3164"},"detectionMethod":"They used the Axiom platform for genome-wide genotyping, followed by analysis using AutoSNP to call homozygous runs. The full coding sequence of this gene was amplified and sequenced using previously published primers and PCR conditions.","firstTestingMethod":"Chromosomal microarray","phenotypeFreeText":"polyarthritis, glomerulonephritis, cutaneous manifestations, hypocomplementemia, ANA, LAC, anti-DNA positivity, interstitial lung disease and intestinal vasculitis","previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/1bb1c8a6-d7d9-472f-aa64-5ee343caa499_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27821515","allele":{"id":"https://genegraph.clinicalgenome.org/r/8ca27d60-178b-4f7e-be35-f09e85eb3164"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}}},"phenotypeFreeText":"mother had undergone kidney transplant for unknown nephropathy at age 50; she had a history of low level complement. \n\none brother, who died in a car accident, had been diagnosed with juvenile idiopathic arthritis\n\nsister had polyarticular arthritis and jaccoud's arthropathy","phenotypeNegativeAlleleNegative":1,"phenotypePositiveAllelePositive":4,"proband":{"id":"https://genegraph.clinicalgenome.org/r/3b1972e8-b2cb-476a-98ce-be8ce1609b0c"}},{"id":"https://genegraph.clinicalgenome.org/r/a0124470-4b8a-4b4c-a4d5-34c7f934fb8a_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22019780","rdfs:label":"Al-Mayouf F1","estimatedLodScore":1.58,"family":{"id":"https://genegraph.clinicalgenome.org/r/a0124470-4b8a-4b4c-a4d5-34c7f934fb8a","type":"Family","rdfs:label":"Al-Mayouf F1","member":{"id":"https://genegraph.clinicalgenome.org/r/85e3bd14-8a7d-43c1-a327-e2e085462aa5"}},"meetsInclusionCriteria":false,"phenotypeFreeText":"anti-nuclear antibody, low c3 and c4","phenotypeNegativeAlleleNegative":3,"phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0020151","obo:HP_0032230"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/85e3bd14-8a7d-43c1-a327-e2e085462aa5"}},{"id":"https://genegraph.clinicalgenome.org/r/bed0c098-ec1c-48f8-9f06-ba8c98855467_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22019780","rdfs:label":"Al-Mayouf F5","estimatedLodScore":3.16,"family":{"id":"https://genegraph.clinicalgenome.org/r/bed0c098-ec1c-48f8-9f06-ba8c98855467","type":"Family","rdfs:label":"Al-Mayouf F5","member":{"id":"https://genegraph.clinicalgenome.org/r/0f132d68-2af9-4d94-a90e-f24d8920e2de"}},"meetsInclusionCriteria":false,"phenotypeFreeText":"anti-nuclear antibody, low c3 and c4","phenotypeNegativeAlleleNegative":6,"phenotypePositiveAllelePositive":5,"phenotypes":"obo:HP_0033726","proband":{"id":"https://genegraph.clinicalgenome.org/r/0f132d68-2af9-4d94-a90e-f24d8920e2de"}},{"id":"https://genegraph.clinicalgenome.org/r/9b33429b-5ecc-4aae-a048-f7cea1810c07_family_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35670985","rdfs:label":"Tusseau Family A","estimatedLodScore":0.25,"family":{"id":"https://genegraph.clinicalgenome.org/r/9b33429b-5ecc-4aae-a048-f7cea1810c07","type":"Family","rdfs:label":"Tusseau Family A"},"meetsInclusionCriteria":false,"phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":1},{"id":"https://genegraph.clinicalgenome.org/r/77f282b7-5828-4cfa-b9e5-27d4cbafa57a_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35670985","rdfs:label":"Tusseau Family E","family":{"id":"https://genegraph.clinicalgenome.org/r/77f282b7-5828-4cfa-b9e5-27d4cbafa57a","type":"Family","rdfs:label":"Tusseau Family E","member":{"id":"https://genegraph.clinicalgenome.org/r/64c0b894-d8df-4609-9d7d-f0e877c25187"}},"phenotypePositiveAllelePositive":1,"proband":{"id":"https://genegraph.clinicalgenome.org/r/64c0b894-d8df-4609-9d7d-f0e877c25187"}},{"id":"https://genegraph.clinicalgenome.org/r/cd46ff06-c689-4507-bbf6-be36cee08a6b_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22019780","rdfs:label":"Al-Mayouf F6","estimatedLodScore":1.23,"family":{"id":"https://genegraph.clinicalgenome.org/r/cd46ff06-c689-4507-bbf6-be36cee08a6b","type":"Family","rdfs:label":"Al-Mayouf F6","member":{"id":"https://genegraph.clinicalgenome.org/r/7ff944d8-e6e2-49b6-9a6a-b4aab8c930b8"}},"meetsInclusionCriteria":false,"phenotypeFreeText":"anti-nuclear antibody, low c3 and c4","phenotypeNegativeAlleleNegative":5,"phenotypePositiveAllelePositive":2,"phenotypes":"obo:HP_0020151","proband":{"id":"https://genegraph.clinicalgenome.org/r/7ff944d8-e6e2-49b6-9a6a-b4aab8c930b8"}},{"id":"https://genegraph.clinicalgenome.org/r/bb5e41ff-dbc5-4900-881c-59ac47768684_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22019780","rdfs:label":"Al-Mayouf F3","estimatedLodScore":0.73,"family":{"id":"https://genegraph.clinicalgenome.org/r/bb5e41ff-dbc5-4900-881c-59ac47768684","type":"Family","rdfs:label":"Al-Mayouf F3","member":{"id":"https://genegraph.clinicalgenome.org/r/427b79d8-6922-4480-aacd-5e961e67885f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22019780","rdfs:label":"Al-Mayouf F3-A","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":3,"allele":{"id":"https://genegraph.clinicalgenome.org/r/f023dc4c-022d-4ebe-9f1b-f9a6cf2bf8ac"},"detectionMethod":"Autozygome analysis identified overlapping autozygous intervals of varying lengths at 3p14.3 among six consanguinenous families affected by SLE. Linkage analysis confirmed this to be a genuine linkage locus with LOD score 6.6. The minimal linkage interval contained 206 genes, including DNASE1L3. DNASE1L3 was identified as a top candidate gene and subsequently sequenced.","firstTestingMethod":"Linkage analysis","phenotypeFreeText":"anti-nuclear antibody, low c3 and c4; SLE activity index 18","phenotypes":["obo:HP_0033726","obo:HP_0032230","obo:HP_0020151"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/1a0733be-ea40-4d88-abb3-3d16d360e74c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22019780","allele":{"id":"https://genegraph.clinicalgenome.org/r/f023dc4c-022d-4ebe-9f1b-f9a6cf2bf8ac"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"anti-nuclear antibody, low c3 and c4","phenotypeNegativeAlleleNegative":1,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0020151","obo:HP_0032230","obo:HP_0033726"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/427b79d8-6922-4480-aacd-5e961e67885f"}},{"id":"https://genegraph.clinicalgenome.org/r/322b51d3-4e9a-4e13-9488-69d1f6ede689_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35670985","rdfs:label":"Tusseau Family C","estimatedLodScore":0.25,"family":{"id":"https://genegraph.clinicalgenome.org/r/322b51d3-4e9a-4e13-9488-69d1f6ede689","type":"Family","rdfs:label":"Tusseau Family C","member":{"id":"https://genegraph.clinicalgenome.org/r/2edaab7e-92d5-4414-94f8-3f45831eeaaf","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35670985","rdfs:label":"Tusseau Pt3","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":15,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/8ca27d60-178b-4f7e-be35-f09e85eb3164"},{"id":"https://genegraph.clinicalgenome.org/r/da26f6da-f97d-4e8d-9d04-e7ef618fde41","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004944.4(DNASE1L3):c.321-1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA353340284"}}],"detectionMethod":"\"a panel of 41 key genes involved in autoimmunity has been studied using Illumina technology / The Nimblegen SeqCap Target Enrichment kit (Roche) on a Novaseq 6000 (Illumina)\"","firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"From the age of 15 years-old, she presented with recurrent episodes of fever, accompanied by urticaria, arthralgia and myalgia. Then she presented with a significant anemia (4.5 g/dL) for which she underwent a blood transfusion. She had no renal involvement.  Blood tests showed a pronounced elevation of inflammatory markers, i.e. ESR, CRP, SAA (111 mg/L). ANA was positive (1:160) and the value of ANCA was in the gray zone (0.7).","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/4fcf4096-00cd-4581-ad51-6e7d7c7e993d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35670985","allele":{"id":"https://genegraph.clinicalgenome.org/r/da26f6da-f97d-4e8d-9d04-e7ef618fde41"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/a155a994-55f4-4611-8f8f-a83c20e966bd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35670985","allele":{"id":"https://genegraph.clinicalgenome.org/r/8ca27d60-178b-4f7e-be35-f09e85eb3164"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]}},"phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":1,"proband":{"id":"https://genegraph.clinicalgenome.org/r/2edaab7e-92d5-4414-94f8-3f45831eeaaf"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/2edaab7e-92d5-4414-94f8-3f45831eeaaf_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4fcf4096-00cd-4581-ad51-6e7d7c7e993d","type":"EvidenceLine","dc:description":"The patient did not fulfill diagnostic criteria for lupus.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4fcf4096-00cd-4581-ad51-6e7d7c7e993d_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/a155a994-55f4-4611-8f8f-a83c20e966bd","type":"EvidenceLine","dc:description":"The patient did not fulfill diagnostic criteria for lupus.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a155a994-55f4-4611-8f8f-a83c20e966bd_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"qPCR in a homozygous carrier showed significantly reduced expression; PMID 23666765","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/a155a994-55f4-4611-8f8f-a83c20e966bd_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/2edaab7e-92d5-4414-94f8-3f45831eeaaf"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/427b79d8-6922-4480-aacd-5e961e67885f_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1a0733be-ea40-4d88-abb3-3d16d360e74c","type":"EvidenceLine","dc:description":"Only one proband from the families in the Al Mayouf et al. paper will be scored; these families carry a single variant in DNASE1L3 that may be due to a founder mutation. The evidence would otherwise be overweighted.","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1a0733be-ea40-4d88-abb3-3d16d360e74c_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"No DNASE1L3 transcript was detectable in two patient lymphoblast cell lines carrying the homozygous DNASE1L3 c.643del variant.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/1a0733be-ea40-4d88-abb3-3d16d360e74c_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/427b79d8-6922-4480-aacd-5e961e67885f"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/3b1972e8-b2cb-476a-98ce-be8ce1609b0c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1bb1c8a6-d7d9-472f-aa64-5ee343caa499","type":"EvidenceLine","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1bb1c8a6-d7d9-472f-aa64-5ee343caa499_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"DNASE1L3 deletion causes aberrations in length and end-motif frequencies in plasma DNA.\n","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/1bb1c8a6-d7d9-472f-aa64-5ee343caa499_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/3b1972e8-b2cb-476a-98ce-be8ce1609b0c"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/1bede8ce-3e6a-4fdd-b743-611ae1145730_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fb6c7c57-2406-46d6-936b-5ff611c54463","type":"EvidenceLine","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fb6c7c57-2406-46d6-936b-5ff611c54463_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"qPCR in a homozygous carrier showed significantly reduced expression; PMID 23666765","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/fb6c7c57-2406-46d6-936b-5ff611c54463_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30008451","allele":{"id":"https://genegraph.clinicalgenome.org/r/8ca27d60-178b-4f7e-be35-f09e85eb3164"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/1bede8ce-3e6a-4fdd-b743-611ae1145730","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30008451","rdfs:label":"Batu Patient 6","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":24,"allele":{"id":"https://genegraph.clinicalgenome.org/r/8ca27d60-178b-4f7e-be35-f09e85eb3164"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"fulfills Systemic Lupus International Collaborating Clinics (SLICC) criteria; maculopapular rash; anti-nuclear antibody; hypocomplementemia; anticardiolipin antibodies","phenotypes":["obo:HP_0100532","obo:HP_0000992","obo:HP_0020151","obo:HP_0000123","obo:HP_0025300","obo:HP_0001369"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/fb6c7c57-2406-46d6-936b-5ff611c54463_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/77450e46-30fa-4be0-aa0e-4e31f04a117e_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/77450e46-30fa-4be0-aa0e-4e31f04a117e_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fcc58769-7ca4-4d8f-a485-0f393b415056","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b20a3069-7950-4492-8da0-85db511b022f","type":"Finding","dc:description":"This mouse model develops several typical features of SLE (autoantibodies, nephritis)","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27293190","rdfs:label":"DNASE1L3-deficient mouse model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/5c3f2659-ad5b-483d-8c05-57a11a0ce950","type":"EvidenceLine","dc:description":"It is not the clinical disease phenotype that is rescued. Instead, the study shows rescue of plasma DNA size and motif, which is not the same as clinical disease phenotype.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ad066351-296e-466f-9a65-5a2136a0c18b","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33022220","rdfs:label":"Plasma DNA Profile Associated with DNASE1L3 Gene Mutations:","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/77450e46-30fa-4be0-aa0e-4e31f04a117e_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0ee33a56-040c-417e-ba74-a82705a0b851","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/44110284-ee8c-4952-83e0-6845711e9e88","type":"FunctionalAlteration","dc:description":"There is aberration in size and reduction in of a \"CC\" end motif in plasma DNA in patients with homozygous loss of function mutations of DNASE1L3.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33022220","rdfs:label":"Plasma DNA Profile Associated with DNASE1L3 Gene Mutations:"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/f46d36e6-b54b-45b2-a17b-1cc927682587","type":"EvidenceLine","dc:description":"Crude cell extracts were assayed; however, the wild-type enzyme is secreted.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d7ce8d49-a6c7-42da-be2f-2ea8854ff2a3","type":"FunctionalAlteration","dc:description":"In transfected COS-7 crude cell lysates, the variant protein showed no DNase activity as assayed by single radial enzyme diffusion (SRED) method.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19559017","rdfs:label":"in vitro activity of R206C mutant protein"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/bca42f01-a33d-4ea9-a193-882e27e45590","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b541ff5a-4e2b-436a-ab38-6ced9e4281ca","type":"FunctionalAlteration","dc:description":"DNASE1L3 is released into the circulation to fragment DNA. DNASE1L3-KO mice have aberrant size of plasma DNA in circulation (increase in the very short plasma DNA as well as increase in the longer DNA molecules). There was also an increase in the motifs that started with CC compared to wild-type DNA, suggesting aberrant fragmentation of DNA found in plasma.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30593563","rdfs:label":"Dnase1l3 deletion causes aberrations in length of plasma DNA"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/a8355de9-8754-4dbd-b16e-6fd9928279b2","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/53f2102e-9847-4471-879e-e248f192cc43","type":"FunctionalAlteration","dc:description":"Wild-type DNASE1L3 protein is secreted into supernatants of HEK293 cells transiently expressing the DNASE1L3 gene from 1-day post-transfection, but rDNASE1L3 Arg206Cys protein is not. The variant protein appears to retain DNase activity, and a low level of secretion can sometimes be observed.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33455918","rdfs:label":"DNASE1L3 Arg206Cys protein secretion and enzymatic activity"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/77450e46-30fa-4be0-aa0e-4e31f04a117e_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/13864da9-86b7-4799-8b6b-407f48f374a5","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/84dee0e8-8b40-4f90-b4bf-20efb31a830b","type":"Finding","dc:description":"Quantitative PCR analysis of the cDNA samples obtained from homozygote, heterozygote, and wild-type members of family 1 showed severely reduced levels of DNASE1L3 in homozygotes and a moderate reduction in heterozygotes, as expected due to nonsense-mediated messenger RNA decay that is triggered by the premature termination codon.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23666765","rdfs:label":"DNASE1L3 mutation in HUVS","demonstrates":{"id":"cg:GeneExpressionB"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ca0da6a7-cb98-411a-9a98-e2c0df48cae7","type":"EvidenceLine","dc:description":"question about diagnostic criteria for SLE patients; this cohort had SLEDAI score, mean Â± SD: 7.62 Â± 4.49","calculatedScore":0.5,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ae7290ce-887c-4bf3-9d23-4d8546a369b4","type":"Finding","dc:description":"The average serum DNase1L3 level (measured using commercial ELISA kits) was significantly lower in SLE patient serum compared to control serum.\nDNase activity as measured by digestion of human nucleosomal DNA was significantly lower in SLE patient serum compared to control serum.\nDNase activity was significantly lower in patients with active SLE compared to patients in remission.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28039554","rdfs:label":"expression in SLE patients","demonstrates":{"id":"cg:GeneExpressionB"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/7cb9dbfd-55d0-4b49-923e-6f63310cfd78","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c56e832b-b8d7-4dbe-9ef5-b737b0c28b7b","type":"Finding","dc:description":"RT-PCR with three different primer sets showed no detectable DNASE1L3 transcript in two patient lymphoblast cell lines.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22019780","rdfs:label":"expression in patient cell line","demonstrates":{"id":"cg:GeneExpressionB"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":8445,"specifiedBy":"GeneValidityCriteria10","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/rJ3FqdwEwno","type":"GeneValidityProposition","disease":"obo:MONDO_0013743","gene":"hgnc:2959","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_77450e46-30fa-4be0-aa0e-4e31f04a117e-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}